HCW Biologics (HCWB) Fundamental Analysis: Revenue, Earnings & Valuation

0.25 / 10

Underperform

Fundamental scrutiny indicates challenging standing (0.2/10). Favorable drivers: Fixed assets turnover ratio and ROA (%), however risks emerge in Asset-MV and Income tax / Total profit (%). Investment outlook: challenging.

Analysis Checks(4/10)

ROA (%)

Value-29.07

Score3/3

Weight-184.75%

1M Return1.63%

Total operating revenue (YoY growth rate %)

Value-97.89

Score1/3

Weight171.17%

1M Return-1.62%

PB-ROE

Value0.72

Score1/3

Weight-299.53%

1M Return2.47%

Income tax / Total profit (%)

Value19.90

Score0/3

Weight221.06%

1M Return-2.14%

Fixed assets turnover ratio

Value0.00

Score2/3

Weight72.70%

1M Return-0.65%

Annualized net profit margin on total assets (%)

Value-29.07

Score3/3

Weight-184.75%

1M Return1.63%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight125.45%

1M Return-1.16%

Operating revenue (YoY growth rate %)

Value-97.89

Score1/3

Weight166.09%

1M Return-1.57%

Cost of sales ratio (%)

Value80.00

Score1/3

Weight688.68%

1M Return-8.14%

Asset-MV

Value-0.72

Score1/3

Weight-676.12%

1M Return5.15%

Is HCWB fundamentally strong?

HCWB scores 0.25/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -14677.14% net margin, -0.09 P/E ratio, 0.70 P/B ratio, and 65.67% earnings growth, these metrics solidify its Underperform investment rating.